title: Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule.
abstract: Aiming to increase the potency of synthetic long peptide (SLP)-based cancer vaccines, the Toll-like receptor 2 (TLR2) ligand Pam3CSK4was conjugated in a chemically defined fashion to SLPs harbouring both cytotoxic T lymphocyte (CTL) and T helper epitopes. We recently showed that these SLP-conjugates induce strong antitumor immunity in murine cancer models.
authors.affiliation: Department of Immunohematology and Blood Transfusion; Leiden University Medical Center ; Leiden, The Netherlands.
authors.forename: Gijs G
authors.initials: GG
authors.lastname: Zom
authors.affiliation: Leiden Institute of Chemistry; University of Leiden ; Leiden, The Netherlands.
authors.forename: Dmitri V
authors.initials: DV
authors.lastname: Filippov
authors.affiliation: Leiden Institute of Chemistry; University of Leiden ; Leiden, The Netherlands.
authors.forename: Gijsbert A
authors.initials: GA
authors.lastname: van der Marel
authors.affiliation: Leiden Institute of Chemistry; University of Leiden ; Leiden, The Netherlands.
authors.forename: Hermen S
authors.initials: HS
authors.lastname: Overkleeft
authors.affiliation: ISA Pharmaceuticals ; Leiden, The Netherlands.
authors.forename: Cornelis J
authors.initials: CJ
authors.lastname: Melief
authors.affiliation: Department of Immunohematology and Blood Transfusion; Leiden University Medical Center ; Leiden, The Netherlands.
authors.forename: Ferry
authors.initials: F
authors.lastname: Ossendorp
keywords: SLP; TLR2; Toll-like receptor; Tumor; conjugate; immunotherapy; lymphoma; melanoma; synthetic long peptides; vaccination